Stockscreener 앱 받기
6.90
0.00%
0.00
시장 영업 전:
6.91
0.010
+0.14%
전일 마감가:
$6.90
열려 있는:
$6.9
하루 거래량:
1.48M
Relative Volume:
0.90
시가총액:
$1.19B
수익:
$314.85M
순이익/손실:
$12.01M
주가수익비율:
105.34
EPS:
0.0655
순현금흐름:
$47.52M
1주 성능:
+2.83%
1개월 성능:
+10.58%
6개월 성능:
-1.29%
1년 성능:
+51.98%
1일 변동 폭
$6.785
$7.055
1주일 범위
$6.61
$7.08
52주 변동 폭
$4.4005
$10.08
Xeris Biopharma Holdings Inc Stock (XERS) Company Profile
명칭
Xeris Biopharma Holdings Inc
전화
844-445-5704
주소
1375 WEST FULTON STREET, SUITE 1300, CHICAGO, IL
Compare XERS vs TAK, HLN, TEVA, ZTS, UTHR
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
XERS
Xeris Biopharma Holdings Inc
|
6.90 | 1.19B | 314.85M | 12.01M | 47.52M | 0.0655 |
TAK
Takeda Pharmaceutical Co Adr
|
15.42 | 49.83B | 29.91B | 1.30B | 3.49B | 0.4056 |
HLN
Haleon Plc Adr
|
8.87 | 40.04B | 14.54B | 2.22B | 2.58B | 0.4871 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
32.56 | 39.23B | 17.53B | 1.58B | 444.18M | 1.3457 |
ZTS
Zoetis Inc
|
77.26 | 33.52B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
551.47 | 23.33B | 3.17B | 1.29B | 1.01B | 27.09 |
Xeris Biopharma Holdings Inc Stock (XERS) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-12-09 | 개시 | Barclays | Overweight |
| 2025-08-12 | 재개 | H.C. Wainwright | Buy |
| 2024-11-11 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2024-03-28 | 개시 | Oppenheimer | Outperform |
| 2023-08-28 | 개시 | Craig Hallum | Buy |
| 2022-10-21 | 개시 | Jefferies | Buy |
| 2022-04-28 | 개시 | Craig Hallum | Buy |
| 2021-11-17 | 개시 | SVB Leerink | Outperform |
| 2021-10-29 | 개시 | H.C. Wainwright | Buy |
| 2021-04-07 | 재개 | RBC Capital Mkts | Outperform |
| 2020-02-18 | 개시 | Piper Sandler | Overweight |
| 2018-07-16 | 개시 | Jefferies | Buy |
| 2018-07-16 | 개시 | Leerink Partners | Outperform |
| 2018-07-16 | 개시 | RBC Capital Mkts | Outperform |
모두보기
Xeris Biopharma Holdings Inc 주식(XERS)의 최신 뉴스
Xeris Biopharma Holdings Inc. (XERS) Q1 2026 Earnings: Surprise EPS Profitability Achieved Amid Mixed Market ReceptionDownward Estimate Revision - newsline.com
Jim Cramer Blesses a Caller’s Speculative Investment in Xeris Biopharma - Insider Monkey
Xeris Pharmaceuticals, Inc. (XERS) stock price, news, quote and history - Yahoo Finance UK
Xeris Biopharma Stock (US98422E1038): Debt Exchange Targets $23 Million Of 8% Convertible Notes - AD HOC NEWS
XERS Receives Notice of Allowance for Patent on Keveyis - GuruFocus
Xeris Biopharma Holdings, Inc. (XERS) Latest Stock News & Headlines - Yahoo Finance
XERS Enters Exchange Agreements to Retire Convertible Notes - GuruFocus
Xeris receives patent allowance for Keveyis through 2039 By Investing.com - Investing.com Canada
Xeris Biopharma Announces Notice of Allowance From U.S. Patent and Trademark Office for New Patent Covering KEVEYIS® - lincolnjournal.com
Xeris Biopharma Announces Debt Exchange Agreement to Strengthen Balance Sheet - GuruFocus
Jim Cramer Discussed 15 Stocks, Including Broadcom, Netflix, and His Skepticism Toward Tech Stocks - Insider Monkey
XERS Q1 2026 Earnings: EPS Surprise of 217.65% Drives Stock HigherPre-Announcement Alert - newsline.com
Xeris Biopharma to Retire $23 Million of Convertible Notes Through Private Exchange - marketscreener.com
Xeris to retire $23M of convertible notes through exchange agreements - MSN
Xeris Biopharma Announces Private Exchange of Convertible Notes - BioSpace
Xeris Biopharma (XERS) Retires $23M in Convertible Notes Through Exchange - GuruFocus
Xeris Biopharma to retire $23 million in convertible notes - Investing.com
Xeris Biopharma (NASDAQ: XERS) to retire $23M of 8% notes in cash-and-stock deal - Stock Titan
fastest-growing companies - Crain's Chicago Business
Xeris Biopharma (XERS) Surges 4%: Breaking Past Key Support with Upward MomentumMoving Average Crossovers - newsline.com
XERS Q1 2026 Earnings: EPS Surprise of 217.65% Drives Positive MomentumCapex Guidance - newsline.com
Xeris Biopharma Holdings (XERS) Edges Higher with Steady Support Levels HoldingCall Dominated - newsline.com
Xeris Biopharma director John Johnson sells $91,422 in shares By Investing.com - Investing.com Australia
Xeris Biopharma director Dawn Halkuff sells $121,885 in company stock By Investing.com - Investing.com South Africa
Xeris Biopharma director John Johnson sells $91,422 in shares - Investing.com UK
Xeris Biopharma director Marla Persky sells $91,432 in shares - Investing.com UK
Xeris Biopharma director Marla Persky sells $91,432 in shares By Investing.com - Investing.com Australia
Xeris Biopharma director Bormann-Kennedy sells $97,507 in stock By Investing.com - Investing.com South Africa
Xeris Biopharma director Dawn Halkuff sells $121,885 in company stock - Investing.com
Xeris Biopharma (XERS) director awarded new RSU and stock option grants - Stock Titan
Xeris Biopharma (XERS) director logs stock sale and new equity grants - Stock Titan
Xeris Biopharma director Bormann-Kennedy sells $97,507 in stock - Investing.com
[Form 4] Xeris Biopharma Holdings, Inc. Insider Trading Activity - Stock Titan
Xeris Biopharma (XERS) director trades stock and receives new equity awards - Stock Titan
Xeris Biopharma (XERS) director gets equity grant and 10b5-1 share sale - Stock Titan
Xeris Biopharma (XERS) director receives new RSU and stock option grants - Stock Titan
Xeris Biopharma Shareholders Elect Directors and Ratify Auditor - TipRanks
[8-K] Xeris Biopharma Holdings, Inc. Reports Material Event - Stock Titan
[144] Xeris Biopharma Holdings, Inc. SEC Filing - Stock Titan
XERS: RECORLEV drives robust growth as pipeline and commercial expansion accelerate, with strong financials - TradingView
Beth Hecht Sells 16,667 Shares of Xeris Biopharma Holdings Inc (XERS) - GuruFocus
Xeris Biopharma (XERS) officer sells 16,667 shares in Rule 10b5-1 trade - Stock Titan
XERS Q1 2026 Earnings: Surprise Profitability at Odds with Market SentimentGross Profit Margin - newsline.com
XERS Q1 2026 Earnings: EPS Beat Masks Cautious Outlook as Shares DipEarnings Yield Spread - newsline.com
Xeris Looks Ridiculously Cheap If Growth Forecasts Are Even Halfway Right (NASDAQ:XERS) - Seeking Alpha
Xeris Biopharma Holdings Inc (XERS) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Xeris Biopharma Holdings Inc 주식 (XERS) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| HALKUFF DAWN | Director |
Jun 04 '26 |
Sale |
6.09 |
20,000 |
121,886 |
95,000 |
| BORMANN-KENNEDY BARBARA-JEAN A | Director |
Jun 04 '26 |
Sale |
6.09 |
16,000 |
97,507 |
126,500 |
| JOHNSON JOHN | Director |
Jun 04 '26 |
Sale |
6.09 |
15,000 |
91,422 |
683,083 |
0.95%
1.13%
자본화:
|
볼륨(24시간):